<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>19(4)</volume><submitter>Aigha II</submitter><funding>Hamad bin Khalifa University</funding><pubmed_abstract>The multipotent pancreatic progenitor cells (MPCs) co-expressing the transcription factors, PDX1 and NKX6.1, are the source of functional pancreatic β-cells. The aim of this study was to examine the effect of p53 inhibition in MPCs on the generation of PDX1&lt;sup>+&lt;/sup>/NKX6.1&lt;sup>+&lt;/sup> MPCs and pancreatic β-cell generation. Human embryonic stem cells (hESCs) were differentiated into MPCs and β-cells. hESC-MPCs (stage 4) were treated with different concentrations of p53 inhibitors, and their effect was evaluated using different approaches. NKX6.1 was overexpressed during MPCs specification. Inhibition of p53 using pifithrin-μ (PFT-μ) at the MPC stage resulted in a significant increase in the number of PDX1&lt;sup>+&lt;/sup>/NKX6.1&lt;sup>+&lt;/sup> cells and a reduction in the number of CHGA&lt;sup>+&lt;/s</pubmed_abstract><journal>Stem cell reviews and reports</journal><pagination>942-952</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10185607</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>p53 Inhibition in Pancreatic Progenitors Enhances the Differentiation of Human Pluripotent Stem Cells into Pancreatic β-Cells.</pubmed_title><pmcid>PMC10185607</pmcid><pubmed_authors>Abdelalim EM</pubmed_authors><pubmed_authors>Aigha II</pubmed_authors></additional><is_claimable>false</is_claimable><name>p53 Inhibition in Pancreatic Progenitors Enhances the Differentiation of Human Pluripotent Stem Cells into Pancreatic β-Cells.</name><description>The multipotent pancreatic progenitor cells (MPCs) co-expressing the transcription factors, PDX1 and NKX6.1, are the source of functional pancreatic β-cells. The aim of this study was to examine the effect of p53 inhibition in MPCs on the generation of PDX1&lt;sup>+&lt;/sup>/NKX6.1&lt;sup>+&lt;/sup> MPCs and pancreatic β-cell generation. Human embryonic stem cells (hESCs) were differentiated into MPCs and β-cells. hESC-MPCs (stage 4) were treated with different concentrations of p53 inhibitors, and their effect was evaluated using different approaches. NKX6.1 was overexpressed during MPCs specification. Inhibition of p53 using pifithrin-μ (PFT-μ) at the MPC stage resulted in a significant increase in the number of PDX1&lt;sup>+&lt;/sup>/NKX6.1&lt;sup>+&lt;/sup> cells and a reduction in the number of CHGA&lt;sup>+&lt;/s</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-22T08:48:38.407Z</modification><creation>2025-04-05T22:41:15.997Z</creation></dates><accession>S-EPMC10185607</accession><cross_references><pubmed>36707464</pubmed><doi>10.1007/s12015-023-10509-1</doi></cross_references></HashMap>